Skip to main content
. 2022 Aug 18;140(7):756–768. doi: 10.1182/blood.2021015328

Table 2.

Results of the bivariate RMST analyses

OS-HSCT 5 y ΔRMST (mo) 95% CI P
 DDX41MutGL vs Int/Adv  DDX41WT 13.6 8.7 to 18.4 <.001
 DDX41MutGL vs Fav DDX41WT 2.6 –2.7 to 7.9 .3
RFS-HSCT 3 y ΔRMST (mo) 95% CI P
 DDX41MutGL vs Int/Adv  DDX41WT 5.8 3.1 to 8.5 <.001
 DDX41MutGL vs Fav DDX41WT –1.3 –4.0 to 1.4 .3

Analyses were stratified on the clinical trial.